Targeting a specific process to help eliminate dormant HIV-1 in patients
Modulation of ADP-Ribosylation as a Target During HIV-1 Latency and Reactivation
This study is looking at how a specific chemical change in proteins might help wake up hidden HIV-1 cells so that the immune system can find and get rid of them, which could lead to better treatments and possibly a cure for people living with HIV.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10838937 on NIH RePORTER |
What this research studies
This research investigates the role of ADP-ribosylation, a chemical modification of proteins, in the context of HIV-1 latency and reactivation. The approach aims to understand how this modification affects the ability of the immune system to recognize and eliminate dormant HIV-1 cells. By exploring new latency reversing agents (LRAs) that target ADP-ribosylation, the research seeks to improve the effectiveness of treatments that aim to eradicate HIV-1 from the body. Patients may benefit from advancements in therapies that could potentially lead to a cure for HIV-1.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1 who have not achieved viral suppression or are experiencing challenges with current treatments.
Not a fit: Patients who are not infected with HIV-1 or those who have achieved long-term viral suppression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively eliminate dormant HIV-1 reservoirs, potentially curing patients of the virus.
How similar studies have performed: While the approach of targeting ADP-ribosylation in the context of HIV-1 is novel, previous research has shown promise in using other latency reversing agents to activate dormant HIV-1.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Moen, Jack Michael — University of California, San Francisco
- Study coordinator: Moen, Jack Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.